Anavex Life Sciences Corp (AVXL)

[Jonjones325]

Agreed. That was the main take away for me. The more you take, the better. Hopefully the side effect of dizziness is something that subsides over time allowing patients to tolerate the higher dose.

IMO. The company will not proceed without validating this with current patients. I am hopeful that the company switched all patients to the MTD. This will validate the hypotheses given by Ariana. It's a shame they keep us in the dark about the dosage levels in the extension.

So. What new information will they present on the pk data? Obviously they are saving something for the CTAD. You don't do a late breaking oral for - Here are a few more details we didn't include.

They want to have all data in hand before starting this trial. They have x number of months of data for the extension. That data should validate the parameters of the trial design. Why keep it a secret? Presenting it later after the trial has started will have zero affect.

Let's go Missling. Is this main course? Did you save the best for last? Why present this data before a big conference? Is there a method to the madness?